Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Healing process found to backfire in idiopathic pulmonary fibrosis patients

Healing process found to backfire in idiopathic pulmonary fibrosis patients

Researchers link the extreme fatigue in pulmonary fibrosis to loss in body-rejuvenating R.E.M. sleep

Researchers link the extreme fatigue in pulmonary fibrosis to loss in body-rejuvenating R.E.M. sleep

New treatment option for idiopathic pulmonary fibrosis

New treatment option for idiopathic pulmonary fibrosis

Biomarkers identified for idiopathic pulmonary fibrosis

Biomarkers identified for idiopathic pulmonary fibrosis

Enzyme released by mast cells in the lungs could be a new target for asthma

Enzyme released by mast cells in the lungs could be a new target for asthma

Lungs' mast cells could provide new treatment target for asthma, other respiratory disease

Lungs' mast cells could provide new treatment target for asthma, other respiratory disease

New target found for asthma

New target found for asthma

Rare lung disease cells indicate higher death risk

Rare lung disease cells indicate higher death risk

Smoking belies milder disease but worse prognosis for idiopathic pulmonary fibrosis patients

Smoking belies milder disease but worse prognosis for idiopathic pulmonary fibrosis patients

Discovery of key mechanism underlying idiopathic pulmonary fibrosis

Discovery of key mechanism underlying idiopathic pulmonary fibrosis

Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

New form of idiopathic pulmonary fibrosis found

New form of idiopathic pulmonary fibrosis found

Mutations in a gene that helps regulate cell division linked to inherited form of fatal lung disease

Mutations in a gene that helps regulate cell division linked to inherited form of fatal lung disease

Genetic culprits of idiopathic pulmonary fibrosis

Genetic culprits of idiopathic pulmonary fibrosis

Lessons from our patients: development of a warm autopsy program

Lessons from our patients: development of a warm autopsy program

Research could lead to new treatments for idiopathic pulmonary fibrosis

Research could lead to new treatments for idiopathic pulmonary fibrosis

Fndings could lead to a treatment for idiopathic interstitial pneumonia

Fndings could lead to a treatment for idiopathic interstitial pneumonia

Osteopontin protein found to be more common in patients with lung fibrosis

Osteopontin protein found to be more common in patients with lung fibrosis

Promising results from study of Pirfenidone in idiopathic pulmonary fibrosis (IPF) patients

Promising results from study of Pirfenidone in idiopathic pulmonary fibrosis (IPF) patients

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies